IRIS
CASADEI GARDINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.367
NA - Nord America 3.641
EU - Europa 1.964
SA - Sud America 1.371
AF - Africa 94
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 2
Totale 11.447
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.467
SG - Singapore 1.841
CN - Cina 1.127
BR - Brasile 1.120
HK - Hong Kong 569
VN - Vietnam 498
SE - Svezia 494
IT - Italia 397
RO - Romania 266
RU - Federazione Russa 208
DE - Germania 179
AR - Argentina 114
GB - Regno Unito 108
CA - Canada 88
IN - India 67
MX - Messico 63
NL - Olanda 55
BD - Bangladesh 48
FI - Finlandia 47
AT - Austria 45
PL - Polonia 45
ID - Indonesia 44
EC - Ecuador 42
ZA - Sudafrica 42
JP - Giappone 41
FR - Francia 34
ES - Italia 27
CO - Colombia 25
IQ - Iraq 23
TR - Turchia 23
CL - Cile 19
LT - Lituania 18
MA - Marocco 15
VE - Venezuela 15
PY - Paraguay 14
EG - Egitto 10
IE - Irlanda 10
PK - Pakistan 10
UA - Ucraina 10
UZ - Uzbekistan 10
AE - Emirati Arabi Uniti 9
UY - Uruguay 9
AZ - Azerbaigian 8
PH - Filippine 8
DZ - Algeria 7
PE - Perù 7
IR - Iran 6
KE - Kenya 6
BA - Bosnia-Erzegovina 5
BE - Belgio 5
OM - Oman 5
BO - Bolivia 4
EU - Europa 4
HN - Honduras 4
IL - Israele 4
KZ - Kazakistan 4
NI - Nicaragua 4
SA - Arabia Saudita 4
AO - Angola 3
DO - Repubblica Dominicana 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
A1 - Anonimo 2
AL - Albania 2
AU - Australia 2
BB - Barbados 2
BY - Bielorussia 2
CG - Congo 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
HR - Croazia 2
JM - Giamaica 2
KG - Kirghizistan 2
KW - Kuwait 2
LB - Libano 2
MY - Malesia 2
NP - Nepal 2
PA - Panama 2
XK - ???statistics.table.value.countryCode.XK??? 2
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GA - Gabon 1
GT - Guatemala 1
GY - Guiana 1
JO - Giordania 1
KR - Corea 1
LU - Lussemburgo 1
MT - Malta 1
NG - Nigeria 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
SR - Suriname 1
Totale 11.447
Salva come PNG Salva come JPEG
Città #
Dallas 1.527
Singapore 880
Hong Kong 568
Ashburn 302
New York 285
Beijing 241
Shanghai 235
Hefei 220
Ho Chi Minh City 196
Lawrence 149
Princeton 149
Los Angeles 117
São Paulo 95
Hanoi 91
Milan 90
Boardman 55
Moscow 54
Nuremberg 45
Montreal 43
Warsaw 42
Helsinki 37
Rio de Janeiro 37
Tokyo 36
Rome 35
London 34
Munich 33
Orem 31
Poplar 31
Belo Horizonte 30
Stockholm 30
Brooklyn 28
Denver 28
Vienna 28
Cesano Boscone 26
Johannesburg 25
Mexico City 25
Porto Alegre 25
Guangzhou 24
Santa Clara 24
Atlanta 21
Biên Hòa 20
Chicago 20
Da Nang 20
Haiphong 20
Houston 20
Phoenix 20
Brasília 19
Guarulhos 19
Curitiba 18
Ankara 17
Chennai 17
Toronto 17
Amsterdam 15
Frankfurt am Main 15
Romagnano Sesia 14
Boston 13
Manchester 13
Quito 13
Querétaro 12
Shenzhen 12
Brescia 11
Buenos Aires 11
Dhaka 11
Guayaquil 11
Hải Dương 11
Mumbai 11
Salvador 11
Seattle 11
Bologna 10
Can Tho 10
Dublin 10
Recife 10
Tashkent 10
Campinas 9
Hanover 9
Lappeenranta 9
Montevideo 9
San Francisco 9
The Dalles 9
Thái Bình 9
Thái Nguyên 9
Baku 8
Honolulu 8
Naples 8
Santo André 8
Sumaré 8
Washington 8
Wolfhagen 8
Wuxi 8
Baghdad 7
Bắc Giang 7
Bắc Ninh 7
Calgary 7
Columbus 7
Itajaí 7
Jakarta 7
Lấp Vò 7
New Delhi 7
Phủ Lý 7
Piracicaba 7
Totale 6.657
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 388
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 373
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments 358
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 315
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 95
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 85
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 81
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 79
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 78
Combined hepatocellular-cholangiocarcinoma: morpho-molecular updates and considerations 78
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 75
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 73
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 72
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 71
Correction to: Prospective minimally invasive pancreatic resections from the IGOMIPS registry: a snapshot of daily practice in Italy on 1191 between 2019 and 2022 (Updates in Surgery, (2023), 75, 6, (1439-1456), 10.1007/s13304-023-01592-7) 68
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 68
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 66
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 66
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 65
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 64
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 64
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 64
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 64
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 63
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 62
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 62
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 61
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 61
Retrospective Evaluation and Significance of Neutrophil-to-Lymphocyte Ratio Prior to and 1 month Following Microwave Ablation of Hepatocellular Carcinoma 60
Defining and predicting textbook outcomes for perihilar cholangiocarcinoma: analysis of factors improving achievement of desired postoperative outcomes 60
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 59
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 59
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 59
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 58
EUS-GUIDED GASTROENTEROSTOMY FOR MANAGEMENT OF MALIGNANT GASTRIC OUTLET OBSTRUCTION: A PROSPECTIVE SERIES FROM THE PROTECT REGISTRY 57
Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 57
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 57
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 56
Angiogenesis in biliary tract cancer: targeting and therapeutic potential 56
Cholangiocarcinoma: new perspectives for new horizons 56
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 56
Comparing Liver Venous Deprivation and Portal Vein Embolization for Perihilar Cholangiocarcinoma: Is It Time to Shift the Focus to Hepatic Functional Reserve Rather than Hypertrophy? 55
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 54
BRAF-mutated colorectal cancer: Clinical and molecular insights 54
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 54
Mismatch repair deficiency as prognostic factor for stage III small bowel adenocarcinoma: A multicentric international study 53
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 53
Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time? 53
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming 52
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 51
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 51
Platelets and hepatocellular cancer: Bridging the bench to the clinics 51
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 51
Sorafenib for the treatment of unresectable hepatocellular carcinoma: Preliminary toxicity and activity data in dogs 51
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 51
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 50
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 50
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 50
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 50
The Italian Rare Pancreatic Exocrine Cancer Initiative 49
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 49
Minimally Invasive Approach Provides Oncological Benefit in Patients with High Risk of Very Early Recurrence (VER) After Surgery for Intrahepatic Cholangiocarcinoma (iCCA) 48
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 48
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 48
ROS1 rearrangements are uncommon in biliary tract cancers 48
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 47
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 47
The oncologic burden of residual disease in incidental gallbladder cancer: An elastic net regression model to profile high-risk features 47
The prognostic value of the new combined hemo-eosinophil inflammation index (Hei index): A multicenter analysis of anal cancer patients treated with concurrent chemo-radiation 47
Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments 46
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 45
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib 45
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer 44
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis 44
Preoperative Chemotherapy and Resection Margin Status in Colorectal Liver Metastasis Patients: A Propensity Score-Matched Analysis 44
BRCA in gastrointestinal cancers: Current treatments and future perspectives 44
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 44
Atezolizumab and bevacizumab in advanced HCC: ready for prime time? 44
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 43
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 43
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 43
Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials 43
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 43
Over-the-Wire Lumen-Apposing Metal Stent Exchange for Management of a Long-Term Choledochoduodenostomy Dysfunction 43
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 43
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 43
Mtor pathway expression as potential predictive biomarker in patients with advanced neuroendocrine tumors treated with everolimus 43
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study 43
Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison 43
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 42
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 42
Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report 42
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 42
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 42
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study (Targeted Oncology, (2020), 15, 1, (115-126), 10.1007/s11523-020-00698-x) 42
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 42
Metabolic disorders across hepatocellular carcinoma in Italy 42
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 41
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 41
Erratum to “Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life” [Eur J Cancer (2016) 69 (110–118)] (S095980491632487X)(10.1016/j.ejca.2016.10.004) 41
Totale 6.613
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.285
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.285
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202153 0 0 0 0 0 51 1 1 0 0 0 0
2021/2022100 0 0 0 40 2 5 15 22 6 2 0 8
2022/2023842 325 171 70 12 2 123 25 46 49 5 6 8
2023/2024673 35 18 58 54 33 226 75 47 0 11 30 86
2024/20253.046 349 70 73 33 67 254 687 289 397 281 193 353
2025/20267.109 935 1.392 1.551 1.888 1.027 316 0 0 0 0 0 0
Totale 11.900